So, one could develop ligands that exploit the biological function of a bacteria and the points of cell entry to deliver either a knockout punch of an antibacterial payload, the original concept for the Therapeutic Courier that became a Nanoviricide. Or, use those key metabolic points to punch holes in the bacterial cell membrane, this disgorging the contents and killing otherwise resistant bacteria.
Still, you're right. The company is "Nanoviricides, Inc," and not "Nanoviricides and Nanobacteriacides, Inc."